

Figure S1: Real-time PCR of *nos* expression in wildtype and *srrAB* mutant lowoxygen cultures. Wild-type and *srrAB* mutant low-oxygen TSB+G cultures were grown for 6 hours, and RNA was extracted from cell pellets. Expression of *nos* was measured in cDNA synthesized from each RNA sample by real-time PCR. Relative fold expression was calculated using the Livak method (2-ΔΔCt) and normalized to the reference housekeeping gene *sigA*. Data represent the average from n=3 biological samples, error bars = SEM. *P<0.001 Mann-Whitney Rank Sum Test.

Figure S2: Growth analysis of UAMS-1 (wildtype), *nos srrAB* mutant, and *nos srrAB* complement strains. Aerobic TSB-G cultures were inoculated to an $OD_{600} = 0.025$ in TSB-G media and grown at 37°C with aeration (250 RPM; 1:12.5 volume to flask ratio). Growth over a 24-hour period was monitored by tracking OD_{600} measurements (A), CFU/ml by serial dilution plating (B), and pH measurement (C). Data points represent the average of 3 independent experiments and error bars = SEM.

Figure S3: Contributions of saNOS and SrrAB to antibiotic killing. Earlyexponential phase aerobic TSB-G cultures of UAMS-1 (wildtype) and isogenic *nos*, *srrAB*, and *nos srrAB* mutants were treated with final concentrations of either 30 µg/ml ciprofloxacin (A) or 40 µg/ml vancomycin (B), and CFU/ml were monitored at t=0 (just prior to antibiotic treatment), 1, 2, 4, 6, 8 hours post-treatment, as described in Materials and Methods. All data represent the average of n=3 independent experiments, error bars = SEM.

Figure S4: Nitrate and ammonia concentrations in supernatants. Extracellular nitrate and ammonia was measured from supernatants of wild-type, *nos* mutant, *srrAB* mutant, and *nos srrAB* mutant aerobic growth curves in TSB-G media. A. Nitrate measurements B. Ammonia measurements. For both A and B: Samples were collected at $T = 0, 4, 8, 24$ hours after inoculation. Measurements were performed using R-Biopharm kits in 96-well cell culture plates and each supernatant had an n=3 technical replicates and for each condition N=3 biological replicates, error bars = SEM). *P = 0.03 T-test (relative to wildtype).

Figure S5: Bioscreen growth curves. Wildtype, *nos* mutant, *srrAB* mutant, and *nos srrAB* mutant were inoculated to a final $OD_{600} = 0.025$ in TSB-G and were grown untreated or supplemented with either 5 mM nitrate, 1 mM nitrite, or 1 mM ammonia. 200 µl aliquots were dispensed into quadruplicate wells of a Bioscreen C plate. Cultures were incubated in a Bioscreen C plate reader with maximum shaking at 37°C and growth was monitored by measuring the $OD₆₀₀$ every 15 minutes for 24 hours. Graphs are representative of n=3 biological replicates. Black arrows represent the linear region of the graph in which maximum specific growth rates were calculated for Figure 6.

Figure S6: 4-day sepsis infection. UAMS-1 (wildtype; 3.95 x 107 CFU) and isogenic *nos srrAB* (3.9 x 107 CFU) mutant cultures were each retro-orbitally injected into 8-week-old C57BL/6 female mice (n=8 mice per group). Mice were euthanized 4-days postinfection, and organs were processed for CFU/organ determination as described in Materials and Methods. Graphs depict the calculated bacterial burdens for heart (A), kidney (B), spleen (C) and liver (D). The percent weight loss at 4-days post infection of each animal group is also reported (E). For A–E, data are graphed as scatter plots with mean (solid line) and standard deviation (error bars). Two-tailed P-values are reported for all significantly different comparisons to wild-type using a Mann-Whitney Test.

Table S1. List of bacterial strains and plasmids used in this study

Table S2. PCR primers used in this study

Supplemental References:

- 1. Hanahan D. 1983. Studies on transformation of *Escherichia coli* with plasmids. J Mol Biol 166:557-80.
- 2. Kreiswirth BN, Lofdahl S, Betley MJ, O'Reilly M, Schlievert PM, Bergdoll MS, Novick RP. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305:709-12.
- 3. Gillaspy AF, Lee CY, Sau S, Cheung AL, Smeltzer MS. 1998. Factors affecting the collagen binding capacity of *Staphylococcus aureus*. Infect Immun 66:3170-8.
- 4. Sapp AM, Mogen AB, Almand EA, Rivera FE, Shaw LN, Richardson AR, Rice KC. 2014. Contribution of the *nos-pdt* operon to virulence phenotypes in methicillin-sensitive *Staphylococcus aureus*. PLoS One 9:e108868. doi: 10.1371/journal.pone.0108868. eCollection 2014.
- 5. Lewis AM, Matzdorf SS, Endres JL, Windham IH, Bayles KW, Rice KC. 2015. Examination of the *Staphylococcus aureus* nitric oxide reductase (saNOR) reveals its contribution to modulating intracellular NO levels and cellular respiration. Mol Microbiol 96:651-69. doi: 10.1111/mmi.12962. Epub 2015 Mar 16.
- 6. Bruckner R. 1997. Gene replacement in *Staphylococcus carnosus* and *Staphylococcus xylosus*. FEMS Microbiol Lett 151:1-8.
- 7. Sullivan MA, Yasbin RE, Young FE. 1984. New shuttle vectors for *Bacillus subtilis* and *Escherichia coli* which allow rapid detection of inserted fragments. Gene 29:21-6.
- 8. Windham IH, Chaudhari SS, Bose JL, Thomas VC, Bayles KW. 2016. SrrAB Modulates *Staphylococcus aureus* Cell Death through Regulation of *cidABC* Transcription. J Bacteriol 198:1114-22. doi: 10.1128/JB.00954-15.
- 9. Mogen AB, Carroll RK, James KL, Lima G, Silva D, Culver JA, Petucci C, Shaw LN, Rice KC. 2017. *Staphylococcus aureus* nitric oxide synthase (saNOS) modulates aerobic respiratory metabolism and cell physiology. Mol Microbiol 105:139-157. doi: 10.1111/mmi.13693. Epub 2017 May 10.